Acclarent: Can Balloons Open Sinuses and the ENT Device Market?
Executive Summary
Acclarent is developing interventional technology for the sinuses, targeting a clinical specialty unfamiliar with these techniques, in the hope of expanding an under-served device area. But will ENT surgeons welcome the change?
You may also be interested in...
Intersect Follows Leaders In ENT
Following the lead of ENT start-ups like Acclarent and Entellus Medical, Intersect ENT Inc. is introducing a line of stent like implants capable of performing the same role drug-eluting stents played in interventional cardiology. Intersect’s implants provide moderate structural support to tissue that has been cut or dilated through FESS or balloon sinuplasty. But the principal function of the implant isn’t propping open nasal passageways but rather delivering drugs. A trio of clinical studies conducted by the company has found the released steroids produced statistically significant reductions in inflammation, polyp formation, and postoperative adhesions.
Entellus: Helping The Interventional Revolution Balloon In Sinus Therapy
The second company in the US looking to replace certain sinus surgeries with interventional procedures, Entellus is looking to further advance this technology by moving treatment from the OR to the doctor's office.
Entellus: Helping The Interventional Revolution Balloon In Sinus Therapy
The second company in the US looking to replace certain sinus surgeries with interventional procedures, Entellus is looking to further advance this technology by moving treatment from the OR to the doctor's office.